Trial GOG-0283


A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND #120636) in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments:
Randomized: Not Asked
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Huyen Q. Pham, M.D.
Other Trial Staff:  Grace Facio, R.N., Marissa Aldana, D.M., Yvonne Flores, D.M., Kristy Watkins, R.N.

Staff may log in to see study documents.







For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.